Quarterly Report • May 7, 2019
Quarterly Report
Open in ViewerOpens in native device viewer

15
First quarter 2019 Financial report
Published on May 7, 2019 at 7:00 a.m.
IFRS 16 has been implemented in the Group's financial statements since January 1, 2019. Comparative information for the first quarter of 2018 in the business reviewis presented on an unaudited pro forma basis as if the implementation had taken place on January 1, 2018. This information is labelled "pro forma" or "PF". The balance sheet evolution is compared with January 1, 2019, which includes the IFRS 16 impact versus December 31, 2018.
Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators to provide a more consistent and comparable indication of the Group's financial performance indicators adjust IFRS figures for the non-cash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds, classified as equity under IFRS but treated as debt in the underlying statements that would distort the analysis of the Group's underlying performance. The comments on the results made on pages 3 to 9 are on an underlying basis, unless otherwise stated.
Underlying EBITDA up 2% benefiting from forex conversion and largely stable organically/"
Positive net pricing offset lower volumes in automotive, electronics and oil & gas markets, as well as fixed cost inflation.
UnderlyingEBITDA margin remained solid at 22%.
Underlying EPS [3] from continuing operations largely flat.
Total underlying EPS | up 18%, at €2.80, including strong contribution from discontinued polyamide activities.
| Q1 key figures | IFRS | Underlying | ||||
|---|---|---|---|---|---|---|
| (in € million) | Q1 2019 | Q1 2018 PF | % yoy | Q1 2019 | Q1 2018 PF | % yoy |
| Net sales | 2,571 | 2.492 | +3.2% | 2,571 | 2.492 | +3.7% |
| FRITDA | 530 | 414 | +78% | 571 | 558 | +7.4% |
| EBITDA margin | 22.2% | 22.4% | -0.2pp | |||
| FRIT | 778 | 146 | n.m. | 376 | 377 | +1.1% |
| Net financial charges | (54) | ( ( | +3.0% | (88) | (90) | +2.9% |
| Income tax expenses | (53) | (11) | n.m. | (72) | (67) | -8.0% |
| Tax rate | 26.1% | 24.6% | +1.5pp | |||
| Profit from discontinued operations | 65 | 37 | +74% | 82 | 40 | n.m. |
| (Profit) loss attributable to non-controlling interests | (9) | (10) | -6.4% | (a) | (10) | -5.2% |
| Profit attributable to Solvay shareholders | 228 | 107 | n.m. | 289 | 246 | +18% |
| Basic earnings per share (in €) | 2.21 | 1.03 | n.m. | 7.80 | 2.38 | +18% |
| of which from continuing operations | 1.58 | 0.67 | n.m. | 2.01 | 1.99 | +1.0% |
| Capex in continuing operations | (179) | (180) | +0.3% | |||
| FCF to Solvay shareholders from continuing operations |
(91) | 100 | n.m. | |||
| FLF to Solvay shareholders | (32) | 141 | n.m | |||
| ﺎ 4 ﺃ Net financial debt |
(3,297) | (5,797) | ||||
| Underlying leverage ratio | 2.1 |
[3] Earnings per share, basic calculation
(in € million)

Net sales were up +3.2% on the hasis of positive forex
conversion effects. On an organic basis ", sales were mostly flat at +0.5%, with lower volumes offset by higher prices.
The minor effect of reduction in scope [2] is mainly related to the divestment of some remaining soda ash related activities in Egypt in October 2018.
Forex conversion had a positive effect of +3.6%, related to the appreciation of the U.S. dollar and some other currencies, slightly eroded by the further depreciation of the Brazilian real.
Volumes were down -2.7% overall, as a results of the significant decline in demand from the automotive, electronics and oil & gas markets. Advanced Materials, which has a 40% exposure to automotive and electronics, was especially impacted, and customer destocking accentuated the result. The volume drop of the segment was compensated by the continuing double-digit growth in aerospace. Volumes in Advanced Formulations decreased year on year on the back of the lower activity in the shale oil & gas stimulation market in North America. In Performance Chemicals volumes were slightly up, building on solid demand for soda ash primarily.
Prices rose +3.2% across segments, benefiting from transactional forex effects and partly reflecting higher raw material costs. Sales prices rose especially in Performance Chemicals, both for soda ash and peroxides.
(in € million)
(in €)
| 558 | -4 | +20 | -24 | +28 | -10 | +3 | 571 |
|---|---|---|---|---|---|---|---|
| Scope | Forex conversion! & mix |
Volume | Net pricing -0.6% |
Fixed costs |
Equity earnings & other |
||
| 01 2018 PF | +2.4% | Q1 2019 |
Underlying EBITDA was up +2.4% year on year, benefiting from forex conversion effects, and remained largely flat organically " Positive net pricing effects offset lower volumes and fixed cost inflation.
| 2.80 | |||||||
|---|---|---|---|---|---|---|---|
| 2.38 0.39 |
+0.13 | -0.09 | +0.03 | -0.01 | -0.04 | +0.01 | 0.80 |
| cont. ops. 1.99 |
EBITDA Depreciation, amortization financial ರಿ impairments |
Net charges |
Tax base |
Tax rate change Taxes -0.05 |
Non-ctrl interests & other |
cont. ops. 2.01 |
|
| 01 2018 PF | +1 0% | 01 2019 |
Underlying earnings per share [3] were largely flat at €2.01, on a continuing operations basis. Including the contribution from discontinued operations, they were up 18%, at €2.80.
The underlying EBITDA margin remained solid at 22%.
The lower volumes had a -4.3% effect on EBITDA.
Net pricing was up +5.0%, offsetting higher raw material and energy prices incurred in the period and before, especially in Advanced Formulations and Performance Chemicals. Transactional forex effects were slightly positive.
Fixed cost increases had a -1.8% effect. These reflected the expanded production capabilities in Composite Materials, responding to the surging aerospace demand. Wage inflation was partly compensated by excellence programs. The fixed cost increase was also mitigated by the increase in inventories.
Underlying net financial charges (4) were 3% lower, reflecting the impacts of ongoing deleveraging and optimization of the debt structure. Solvay repaid a €0.38 billion bond at 4.63% in June last year, only partly offset by a new €0.30 billion hybrid bond at 4.25%. The optimization will continue in the rest of the year as Solvay will call a €0.70 billion hybrid bond at 4.20% in May 2019.
The underlying tax rate was 26%, slightly higher than in the first quarter of 2018, but in line with the average underlying tax rate in 2018.
The underlying contribution from discontinued operations doubled to €82 million. The polyamide activity, which is due to be sold to BASF, benefitted from strong prices.
[4] Underlying net financial charges include the counted as dividends under IFAS, and thereby excluded from the PGL), as well as the financial charges and realized from the Rusliny) joint venture (part of earnings from associates under FRS, and thereby included in the FRS EBITDA).
[1] Organic growth excludes forex conversion and scope effects, as well as the effect from the implementation of IFRS 16.

Free cash flow to Solvay shareholders from continuing operations was €(91) million versus €100 million in the first quarter of 2018. The decrease is largely attributable to working capital. Total free cash flow to Solvay shareholders was €(32) million, including a strong contribution from discontinued operations.
Free cash flow from discontinued operations was €57 million, compared to €42 million in 2018, reflecting the strong operational performance of the Polyamide business.
Capex from continuing operations was €(179) million, in line with €(180) million in the first quarter of 2018 on a pro forma basis.
Working capital needs were €(294) million, well up versus 2018. The net working capital over sales ratio rose to 16.5% from 13.8% at the start of the year, when the business activity was at a low point. Inventories rose significantly in those businesses mostly affected by the slowdown in automotive, electronics and oil & gas, as customer destocking took its toll.
| (in € million) | ||||||
|---|---|---|---|---|---|---|
| (5,538) | (32) | (148) | (32) | (20) | (27) | (5,797) |
| Hybrid bonds (2,500) |
FCF to Solvay share- holders |
Dividends to Solvay share- holders |
Remeasu- rements (forex) |
In/outflow from M&A |
Changes in scope & other |
Hybrid bonds (2,500) |
| IFRS (3,038) |
Operational impact (180) |
IFRS (3,297) |
||||
| January 1, 2019 |
March 31. 2019 |
Underlying net financial debt " rose to €(5.8) billion, from €(5.5) billion at the start of the year, bringing the underlying leverage ratio at 2.1x. The payment of the interim dividend in January totaled €(148) million. Remeasurements were €(32) million, attributable to the appreciation of the U.S. dollar by 1.9% over the quarter affecting the conversion of U.S. dollar-denominated debt. M&A activities had a net €(20) million impact.
Underlying gross financial debt was €(7.1) billion, including €(2.5) billion perpetual hybrid bonds. In November 2018 Solvay successfully placed a perpetual hybrid bond for €(300) million, which will allow to call the existing €(700) million hybrid bond in May 2019.

Provisions rose from €(3.8) billion to €(3.9) billion due to remeasurement impacts on the liabilities.
The operational deleveraging was €6 million. The net deleveraging on employee benefits, mostly pensions was €26 million. Other provisions were up, mainly due to an additional provision of €(24) million for the simplification plan.
Remeasurements led to an increase in liabilities and are mainly due to the decrease of discount rates by 0.50 percentage point in both the euro and the U.S. dollar zone, partly offset by the return of plan assets.
[1] Underlying net financial debt includes the perpetual hybrid bonds, accounted for as equity under IFRS
[2] Impact of inflation, mortality, forex & discount rate changes

| Segment review | Underlying | ||
|---|---|---|---|
| (in € million) | Q1 2019 | Q1 2018 PF | % yoy |
| Net sales | 2,571 | 2,492 | +3.2% |
| Advanced Materials | 1,124 | 1,087 | +3.4% |
| Advanced Formulations | 728 | 730 | -0.4% |
| Performance Chemicals | 718 | 671 | +7.0% |
| Corporate & Business Services | 2 | ব | -49% |
| FRITDA | 571 | 558 | +2.4% |
| Advanced Materials | 290 | 295 | -1.8% |
| Advanced Formulations | 126 | 121 | +4.2% |
| Performance Chemicals | 206 | 185 | +11% |
| Corporate & Business Services | (51) | (44) | -17% |
| FRIT | 376 | 372 | +1.1% |
| Advanced Materials | 209 | 219 | -4.8% |
| Advanced Formulations | 87 | 85 | +2.7% |
| Performance Chemicals | 153 | 134 | +14% |
| Corporate & Business Services | (73) | (୧୧) | -11% |
Underlying EBITDA costs were €(51) million, €(7) million more than in 2018, of which €(5) million is linked to scope and forex conversion.
[i] The net sales and EBTDA pie charts exclude Corporate & Business Services had no material contribution to net sales and their contribution to EBITDA is negative, and therefore cannot be depicted
The drop in demand in automotive and electronics markets was exacerbated by customer destocking. This was mitigated by the double-digit volume growth in aerospace driven by commercial and military program.
| Key figures | Underlying | ||
|---|---|---|---|
| (in € million) | Q1 2019 | Q1 2018 PF | % yoy |
| Net sales | 1,124 | 1,087 | +3.4% |
| Specialty Polymers | 480 | 511 | -6.1% |
| Composite Materials | 321 | 255 | +26% |
| Special Chem | 210 | 211 | -0.3% |
| Silica | 113 | 110 | +3.0% |
| EBITDA | 290 | 295 | -1.8% |
| EBITDA margin | 25.8% | 27.1% | -1.4pp |
| EBIT | 209 | 219 | -4.8% |

Net sales were up +3.4% due to forex conversion effects and
remained largely flat organically ". Double digits growth in Composite Materials was not sufficient to overcome the impact of lower demand from the automotive and electronics sector on Specialty Polymers and Special Chem.
Specialty Polymers volumes were down about -10% year on year, partly compensated by better prices. The largest impact came from the electronics applications as investments in the semiconductor industry have significantly reduced and sales for smart device components have declined further. In the automotive market, production figures continued to come down since mid-2018, leading to lower year on year sales beginning in the first quarter, exacerbated by temporary destocking effects. The trend toward fuel-efficiency and electrification supported volume growth in battery materials, albeit from a small base, and demand for healthcare applications remained strong.
Composite Materials volumes grew by some +20%, firmly in the double digits range, as in the second half of 2018. Growth was broad-based in commercial aircraft platforms, including the new single-aisle aircrafts utilizing the LEAP engine technology and the 787 Dreamliner. Initial sales were also realized for the upcoming 777X program. The ramp-up of the military F-35 Joint Strike Fighter also continued at high pace.
The volume decrease in Special Chem follows weak automotive demand. Moreover, demand for diesel cars remained low, negatively impacting the catalyst sales mix. In electronics, market share gains helped offset slower overall demand in the sector.
Silica sales were slightly up, benefiting from robust demand from the fuel-efficient tire market in the year and a better mix.
Underlying EBITDA was down -1.8% including forex conversion
effects, and -5.7% organically ", largely attributable to the lower volumes and mix effects. Excellence measures to improve production yield and optimize the supply chain were not sufficient to compensate higher variable costs, mainly the cost of Fluorspar affecting Special Chem. The underlying EBITDA margin remained solid at 26%, but 1.4 percentage point lower than in the first quarter of 2018.
[1] Excluding forex conversion and scope effects, as well as the effect from the implementation of IFRS 16
Underlying EBITDA up +4.2% overall, and down -1.7% organically ", due to lower oil & gas volumes, partly offset by positive net pricing.
Demand from the oil & gas stimulation market in North America was down year on year, but stabilized versus the fourth quarter of 2018. Other markets, including mining, remained overall supportive.
| Key figures | Underlying | ||
|---|---|---|---|
| (in € million) | Q1 2019 | Q1 2018 PF | % yoy |
| Net sales | 728 | 730 | -0.4% |
| Novecare | 478 | 495 | -3.6% |
| Technology Solutions | 144 | 143 | +0.6% |
| Aroma Performance | 106 | 92 | +15% |
| EBITDA | 126 | 121 | +4.2% |
| EBITDA margin | 17.3% | 16.6% | +0.8pp |
| EBIT | 87 | 85 | +2.7% |

Net sales were flat year on year, sypported by forex conversion
effects and down -4.4% organically '', due to lower volumes in oil & gas, mitigated by higher prices.
In Novecare, volumes were down year on year as a result of lower activity levels in the shale oil & gas stimulation market in North America since September 2018. Market conditions have overall stabilized to slightly improved compared to the fourth quarter of 2018, but are down compared to a strong first quarter in 2018 on a year-on-year basis. Volumes in other end-markets were lower as well, mainly due to weaker agro and industrial markets, but were compensated by better pricing.
Technology Solutions delivered sales in line with 2018 with higher prices compensating for slightly lower volumes. While the mining sector remained supportive, demand for polymer additives from the automotive sector was down.
In Aroma Performance, sales were well up, thanks to volumes and prices, both in polymerization inhibitors and in vanillin ingredients.
Underlying EBITDA was up +4.2% thanks to forex conversion
effects, and was -1.7% down organically ", as a result of lower volumes. These were partly offset by higher net pricing, with the price increases more than compensating for higher raw materials and energy costs. The underlying EBITDA margin thereby remained at 17%.
[1] Excluding forex conversion and scope effects, as well as the effect from the implementation of IFRS 16.
Underlying EBITDA up +11% overall, and up +9.9% organically14, thanks to higher prices, which more than compensated higherraw material and energy costs.
Volumes remained solid in the soda ash and peroxides businesses.
| Key figures | Underlying | ||
|---|---|---|---|
| (in € million) | Q1 2019 | Q1 2018 PF | % yoy |
| Net sales | 718 | 671 | +7.0% |
| Soda Ash & Derivatives | 408 | 371 | +9.9% |
| Peroxides | 172 | 154 | +12% |
| Coatis "J | 138 | 146 | -5.4% |
| EBITDA | 206 | 185 | +11% |
| EBITDA margin | 28.8% | 27.6% | +1.1pp |
| EBIT | 153 | 134 | +14% |

Net sales jin the segment were up 7.0% overall and 7.4%
organically . The scope reduction from the sale of the remaining soda ash assets in Egypt was offset by forex conversion. Volumes and especially prices increased in Soda Ash & Derivatives and in Peroxides, more than compensating for weaker market conditions in Coatis.
In Soda Ash & Derivatives, demand remained strong, and soda ash volumes rose slightly, mainly in the seaborne market. Average soda ash prices were well up, as expected, following the price negotiations concluded at the end of 2018. Sales of bicarbonate, used in more specialized applications, were flat.
Peroxides volumes held on firmly, driven by good demand in the PO markets, while demand in the wood pulp market remained largely stable. Prices were globally up, with a significant increase in Europe more than compensating for the high volatility in Asia. Prices in the region came down from 2018, when these had benefitted from supply constraints.
Coatis sales were down, mostly on lower export volumes of nylon salt, phenol and acetics from its Latin-American home base. Prices were down in local currency.
Underlying EBITDA rose +11%, of which 9.9% organically "1 excluding forex conversion. Higher prices and excellence programs more than compensated higher raw material and energy costs. Volumes were supportive and the contribution of PVC joint venture Rusvinyl increased. Thanks to higher pricing, the EBITDA margin grew +1.1 percentage point to 29% in the quarter.
Since 2019, Coatis incorporates the Fibras activities Polymers. As a result Finctional Polymers only consists of the PVC joint verture Rusyiny, which does not contribute to net sales.
Excluding forex conversion and scope effects, as well as the effect from the implementation of IFRS 16.
Solvay measures its financial performance metrics, which can be found below. Solvay believes that these measurements are useful for analyzing and explaining changes and trends in its historical results of operations, as they allow performance to be compared on a consistent basis. For comparability purposes the 2018 reference figures are on a pro forma been implemented in 2018. The balance sheet evolution is compared with January 1, 2019, which includes the IFRS 16 impact versus December 31, 2018.
| ax rate | Underlying | ||
|---|---|---|---|
| (in € million) | Q1 2019 Q1 2018 PF | ||
| Profit for the period before taxes | a | 288 | 282 |
| Earnings from associates & joint ventures | D | 19 | 17 |
| Interests and realized foreign exchange gains (losses) on the RusVinyl joint venture | ﮯ | (7) | (7) |
| Income taxes | 0 | (72) | 67) |
| Tax rate | e = -d/(a-b-c) | 26.1% | 24.6% |
Underlying tax rate = Income taxes / (Result before taxes - Earnings from associates & joint ventures - Interests & realized foreign exchange results on the RusViny) - all determined on an underlying basis. The adjustment made to the denominator regarding associates and joint ventures is done because these contributions are already net of income taxes.
| (in € million) | Q1 2019 | Q1 2018 PF | |
|---|---|---|---|
| Cash flow from operating activities | a | 172 | 347 |
| Cash flow from investing activities | b | (192) | (142) |
| of which capital expenditures required by share sale agreement | C | (14) | (ਰ) |
| Acquisition (-) of subsidiaries | d | (2) | (10) |
| Acquisition (-) of investments - Other | e | (2) | (1) |
| Loans to associates and non-consolidated companies | f | 2 | |
| Sale (+) of subsidiaries and investments | g | (2) | 50 |
| Payment of lease liabilities | (21) | (23) | |
| FCF | k = a+b-c-d-e-f-g+i | (24) | 152 |
| FCF from discontinued operations | 58 | 42 | |
| FCF from continuing operations | m = k- | (83) | 110 |
| Net interests paid | n | (3) | (ਰ) |
| Coupons paid on perpetual hybrid bonds | 0 | (3) | |
| Dividends paid to non-controlling interests | p | (2) | (1) |
| FCF to Solvay shareholders | q = k+n+0+p | (32) | 141 |
| FCF to Solvay shareholders from discontinued operations | 58 | 42 | |
| FCF to Solvay shareholders from continuing operations | S = Q-r | (91) | 100 |
Free cash flow is calculated as cash flows from operating activities (excluding cash flows linked to acquisitions or disposals of subsidiaries), cash flows from investing activities (excluding cash flows from or related to aquisitions and other investments, and excluding loans to associated investments, as well as related tax elements and recognition of factored receivables) and payment of lease liabilities. Prior to the adoption of IFRS 16, operating lease included in the free cash flow. Following the application of IFRS 16, because leases are generally considered to be operating in nature, the free cash flow incorporates the payment of the lease liability (excluding this item in the free cash flow would result in a significant improvement of the free cash flow compared to prior periods, whereas the operations have not been affected by the implementation of IFRS 16.
Free cash flow to Solvay shareholders is calculated as free cash flow after payment of net interests, coupons of perid bonds and dividends to non-controlling interests. This represents the cash flow available to Solvay shareholders, to reduce the net financial debt.
| (in € million) | Q1 2019 | Q1 2018 PF | |
|---|---|---|---|
| Acquisition (-) of tangible assets | a | (155) | (158) |
| Acquisition (-) of intangible assets | D | (27) | (26) |
| Payment of lease liabilities | (21) | (23) | |
| Capex | d = a+b+c | (202) | (207) |
| Capex in discontinued operations | e | (23) | (27) |
| Capex in continuing operations | f = d-e | (179) | (180) |
| Underlying EBITDA | ತ | 571 | 533 |
| Cash conversion | h = (f+g)/g | 68.7% | 66.3% |
Capex is defined as cash paid for the acquisition of tangible assets presented in cash flows from investing activities, and cash paid on the lease liabilities (excluding interests paid), presented in cash flows from financing activities.
Cash conversion is a ratio used to measion of EBITDA into cash. It is defined as (Underlying EBITDA + Capex from continuing operations) / Underlying EBITDA.
| Net working capital | 2019 | 2018 | ||
|---|---|---|---|---|
| (in € million) | March 31 |
January | December | |
| Inventories | ದ | 1.827 | 1.685 | 1,685 |
| Trade receivables | b | 1.612 | 1.434 | 1,434 |
| Other current receivables | C | 683 | 718 | 719 |
| Trade payables | d | (1,337) | (1,431) | (1,439) |
| Other current liabilities | e | (901) | (850) | (850) |
| Net working capital | f = a+h+c+d+e | 1.884 | 1,557 | 1.550 |
| Sales | g | 2.859 | 2.830 | 2.830 |
| Annualized quarterly total sales | h = 4*g | 11,437 | 11,321 | 11,321 |
| Net working capital / sales | i = f / h | 16.5% | 13.8% | 13.7% |
Net working capital includes inventories, trade receivables, netted with trade payables and other current liabilities.
| Net financial debt | 2019 | 2018 | ||
|---|---|---|---|---|
| March 31 |
January | December | ||
| (in € million) | 31 | |||
| Non-current financial debt | a | (3,561) | (3,520) | (3,180) |
| Current financial debt | b | (1,091) | (723) | (630) |
| IFRS gross debt | c = a+b | (4,652) | (4,243) | (3,810) |
| Other financial instruments | d | 94 | 101 | 101 |
| Cash & cash equivalents | e | 1,261 | 1,103 | 1,103 |
| Total cash and cash equivalents | f = d+e | 1,354 | 1.205 | 1,205 |
| IFRS net debt | g = c+f | (3,297) | (3,038) | (2,605) |
| Perpetual hybrid bonds | h | (2,500) | (2,500) | (2,500) |
| Underlying net debt | i = g+h | (5,797) | (5,538) | (5,105) |
| Underlying EBITDA (last 12 months) | 2,344 | 2,330 | 2,230 | |
| Adjustment for discontinued operations | k | 357 | 315 | 305 |
| Adjusted underlying EBITDA for leverage calculation | = +k | 2,700 | 2,645 | 2,536 |
| Underlying leverage ratio | m = -i/l | 2.1 | 2.1 | 2.0 |
(IFRS) net debt = Non-current financial debt + Current financial debt - Cash equivalents - Other financial instruments. Underlying net debt represents the Solvay share view of debt 100% of the hybrid perpetual bonds, classified as equity under IFRS. Leverage ratio = Net debt / Underlying EBITDA of last 12 months. Underlying net debt / Underlying EBITDA of last 12 months.
[1] As net debt at the end of the period doss not yet proceeds to be received on the divestmant of discontinued operations, whereas the underling EBITA excludes the contribution of discontinued operations EBITDA is adjusted to calculate the leverage ratio. Polyamide's underlying EBITDA was added
Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators to provide a more consistent and comparable indication of Solvay's economic performance. These figures for the non-cash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds classified as equity under IFRS but treated as debt in the underlying statements, and for other elements to generate a measure that avoids distortion and facilitates the appreciation of performance and comparability of results over time. For comparability purposes the 2018 reference figures as if IFRS 16 had been implemented in 2018.
| Q1 consolidated income statement | 01 2019 | Q1 2018 PF | ||||
|---|---|---|---|---|---|---|
| Adjust- | Under- | Adjust- | Under- | |||
| (in € million) | IFRS | ments | lying | IFRS | ments | lying |
| Sales | 2,859 | 2,859 | 2,809 | 2,809 | ||
| of which revenues from non-core activities | 288 | 288 | 317 | 317 | ||
| of which net sales | 2,571 | 2,571 | 2,492 | 2,492 | ||
| Cost of goods sold | (2,088) | (2,088) | (2,062) | (2,062) | ||
| Gross margin | 771 | 772 | 746 | 746 | ||
| Commercial costs | (ae) | (96) | (ਰੇ।) | (91) | ||
| Administrative costs | (246) | 8 | (238) | (238) | 8 | (230) |
| Research & development costs | (79) | 1 | (78) | (70) | 1 | (еа) |
| Other operating gains & losses | (48) | 46 | (3) | (50) | 49 | (1) |
| Earnings from associates & joint ventures | 26 | (7) | 19 | 11 | 6 | 17 |
| Result from portfolio management & reassessments | (35) | 35 | (145) | 145 | ||
| Result from legacy remediation & major litigations | (16) | 16 | (18) | 18 | ||
| EBITDA | 530 | 41 | 571 | 414 | 144 | 558 |
| Depreciation, amortization & impairments | (251) | 56 | (195) | (268) | 82 | (186) |
| EBIT | 278 | 98 | 376 | 146 | 226 | 372 |
| Net cost of borrowings | (31) | (31) | (36) | (36) | ||
| Coupons on perpetual hybrid bonds | (31) | (31) | (27) | (27) | ||
| Interests and realized foreign exchange gains (losses) on the RusVinyl joint venture |
(7) | (7) | (7) | (7) | ||
| Cost of discounting provisions | (23) | 4 | (20) | (19) | (19) | |
| Profit for the period before taxes | 225 | 63 | 288 | ਰ1 | 191 | 282 |
| Income taxes | (23) | (20) | (72) | (11) | (56) | (67) |
| Profit for the period from continuing operations | 172 | 44 | 216 | 79 | 136 | 215 |
| Profit (loss) for the period from discontinued operations |
65 | 18 | 82 | 37 | 3 | 40 |
| Profit for the period | 737 | 61 | 298 | 117 | 139 | 255 |
| attributable to Solvay shareholders | 228 | E1 | 289 | 107 | 139 | 246 |
| attributable to non-controlling interests | 9 | 9 | 10 | 10 | ||
| Basic earnings per share (in €) | 2.21 | 2.80 | 1.03 | 2.38 | ||
| of which from continuing operations | 1.58 | 2.01 | 0.67 | 1.99 | ||
| Diluted earnings per share (in €) | 2.20 | 2.79 | 1.03 | 2.36 | ||
| of which from continuing operations | 1.58 | 2.00 | 0.67 | 1.98 |
EBITDA on an IFRS basis totaled €530 million on an underlying basis. The difference of €41 million is explained by the following adjustments to IFRS results, which are done to improve the comparability of underlying results:
EBIT on an IFRS basis totaled €278 million on an underlying basis. The difference of €98 million is explained by the above-mentioned £41 million adjustments at the EBITDA level and €56 million of "Depreciation 6 impairments". The latter consist of:
Net financial charges on an IFRS basis were €(53) million on an underlying basis. The €(34) million adjustment made to IFRS net financial charges consists of:
Income taxes on an IFRS basis were €(53) million on an underlying basis. The €(20) million adjustment includes mainly:
Discontinued operations generated a profit of €65 million on an IFRS basis and €82 million on an underlying basis. The €18 million adjustment to the IFRS profit is made for costs related to the planned divestment of the polyamide activities.
Profit attributable to Solvay share was €228 million on an underlying basis. The delta of €61 million reflects the above-mentioned adjustments to EBT, net financial charges, income taxes and discontinued operations. There was no impact from non-controlling interests.
| Consolidated income statement | IFRS | |
|---|---|---|
| (in € million) | Q1 2019 | Q1 2018 |
| Sales | 2,859 | 2,809 |
| of which revenues from non-core activities | 288 | 317 |
| of which net sales | 2,571 | 2,492 |
| Cost of goods sold | (2,088) | (2,064) |
| Gross margin | 771 | 744 |
| Commercial costs | (96) | (91) |
| Administrative costs | (246) | (238) |
| Research & development costs | (79) | (70) |
| Other operating gains & losses | (48) | (50) |
| Earnings from associates & joint ventures | 26 | 11 |
| Result from portfolio management & reassessments | (35) | (145) |
| Result from legacy remediation & major litigations | (16) | (18) |
| FRIT | 278 | 144 |
| Cost of borrowings | (36) | (34) |
| Interest on lendings & deposits | 3 | 3 |
| Other gains & losses on net indebtedness | 2 | (1) |
| Cost of discounting provisions | (23) | (19) |
| Profit for the period before taxes | 225 | ਰਤੋ |
| Income taxes | (53) | (12) |
| Profit for the period from continuing operations | 172 | 81 |
| attributable to Solvay shareholders | 163 | 71 |
| attributable to non-controlling interests | 9 | 10 |
| Profit (loss) for the period from discontinued operations | 65 | 37 |
| Profit for the period | 237 | 118 |
| attributable to Solvay shareholders | 228 | 109 |
| attributable to non-controlling interests | 9 | 10 |
| Weighted average of number of outstanding shares, basic | 103,223,084 | 103,354,210 |
| Weighted average of number of outstanding shares, diluted | 103,536,638 | 103,917,063 |
| Basic earnings per share (in €) | 2.21 | 1.05 |
| of which from continuing operations | 1.58 | 0.69 |
| Diluted earnings per share (in €) | 2.20 | 1.04 |
| of which from continuing operations | 1.58 | 0.68 |
| Consolidated statement of comprehensive income | IFRS | ||
|---|---|---|---|
| (in € million) | 01 2019 | 01 2018 | |
| Profit for the period | 237 | 118 | |
| Gains and losses on hedging instruments in a cash flow hedge | 8 | ||
| Currency translation differences from subsidiaries & joint operations | 174 | (166) | |
| Currency translation differences from associates & joint ventures | 23 | (12) | |
| Recyclable components | 197 | (170) | |
| Gains and losses on equity instruments measured at fair value through other comprehensive income | (1) | ||
| Remeasurement of the net defined benefit liability | (74) | 25 | |
| Non-recyclable components | (73) | 74 | |
| Income tax relating to components of other comprehensive income | 22 | (4) | |
| Other comprehensive income, net of related tax effects | 147 | (150) | |
| Total comprehensive income | 384 | (32) | |
| attributed to Solvay share | 372 | (40) | |
| attributed to non-controlling interests | 12 | 9 |
[1] The remeasurement of the net defined benefit liability of €(74) million in Q1 2019 mainly relates of discount rates by 0.50 percentage point in both the euro and the U.S. dollar zone, partly offset by the return of plan assets.
| (in € million) | Q1 2019 | Q1 2018 |
|---|---|---|
| Profit for the period | 237 | 118 |
| Adjustments to profit for the period | 433 | 463 |
| Depreciation, amortization & impairments (-) | 251 | 245 |
| Earnings from associates & joint ventures (-) | (26) | (11) |
| Additions & reversals on provisions (-) | 71 | 168 |
| Other non-operating and non-cash items | 16 | (21) |
| Net financial charges (-) | 54 | 52 |
| Income tax expenses (-) | 67 | 30 |
| Changes in working capital | (332) | (141) |
| Uses of provisions | (96) | (90) |
| Dividends received from associates & joint ventures | б | 5 |
| Income taxes paid (including income taxes paid on sale of investments) | (75) | (35) |
| Cash flow from operating activities | 172 | 320 |
| Acquisition (-) of subsidiaries | (2) | (10) |
| Acquisition (-) of investments - Other | (2) | (1) |
| Loans to associates and non-consolidated companies | 2 | 1 |
| Sale (+) of subsidiaries and investments | (2) | 50 |
| Acquisition (-) of tangible and intangible assets (capex) | (181) | (184) |
| of which tangible assets | (155) | (158) |
| of which capital expenditures required by share sale agreement | (14) | (a) |
| of which intangible assets | (27) | (26) |
| Sale (+) of tangible & intangible assets | 1 | 7 |
| Changes in non-current financial assets | (a) | (5) |
| Cash flow from investing activities | (192) | (142) |
| Sale (acquisition) of treasury shares | б | 2 |
| Increase in borrowings | 390 | 374 |
| Repayment of borrowings | (13) | (410) |
| Changes in other current financial assets | ব | (7) |
| Payment of lease liabilities | (21) | |
| Net interests paid | (3) | (5) |
| Coupons paid on perpetual hybrid bonds | (3) | |
| Dividends paid | (150) | (144) |
| of which to Solvay shareholders | (148) | (143) |
| of which to non-controlling interests | (2) | (1) |
| Other "J | (42) | 24 |
| Cash flow from financing activities | 168 | (166) |
| Net change in cash and cash equivalents | 147 | 12 |
| Currency translation differences | 10 | (14) |
| Opening cash balance | 1,103 | 992 |
| Closing cash balance | 1,261 | 990 |
| (in € million) | 01 2019 | 01 2018 |
|---|---|---|
| Cash flow from operating activities | 68 | ല്ല |
| Cash flow from investing activities | (24) | (24) |
| Cash flow from financing activities | (3) | |
| Net change in cash and cash equivalents | 41 | 42 |
[1] Other cash flow from financing actively impacted in 2018 and negatively in 2019 by cash flows related to margin calls.
| Consolidated statement of financial position | 2019 | 2018 | |
|---|---|---|---|
| (in € million) | March 31 |
January | December 31 |
| Intangible assets | 2,856 | 2,861 | 2,861 |
| Goodwill | 5,236 | 5,173 | 5,173 |
| Tangible assets | 5,479 | 5.454 | 5,454 |
| Rights-of-use assets | 470 | 428 | |
| Equity instruments measured at fair value through other comprehensive income | 54 | 51 | 51 |
| Investments in associates & joint ventures | 484 | 441 | 441 |
| Other investments | 40 | 41 | 41 |
| Deferred tax assets | 1,142 | 1,123 | 1,123 |
| Loans & other assets 17 | 289 | 272 | 282 |
| Non-current assets | 16,050 | 15,844 | 15,427 |
| Inventories | 1,827 | 1,685 | 1,685 |
| Trade receivables | 1,612 | 1,434 | 1,434 |
| Income tax receivables | 136 | 97 | 97 |
| Other financial instruments | ਰੇਖੋ | 101 | 101 |
| Other receivables 131 | 683 | 718 | 719 |
| Cash & cash equivalents | 1,261 | 1,103 | 1,103 |
| Assets held for sale | 1,517 | 1,453 | 1,434 |
| Current assets | 7,130 | 6,592 | 6,574 |
| Total assets | 23,180 | 22,436 | 22,000 |
| Share capital | 1,588 | 1,588 | 1,588 |
| Reserves நி | 9,306 | 8,927 | 8,920 |
| Non-controlling interests | 128 | 117 | 117 |
| Total equity | 11,023 | 10,632 | 10,624 |
| Provisions for employee benefits | 2,746 | 2,672 | 2,672 |
| Other provisions | 861 | 868 | 883 |
| Deferred tax liabilities | ୧ୀମ | 618 | 618 |
| Financial debt | 3,561 | 3,520 | 3,180 |
| Other liabilities | 126 | 121 | 121 |
| Non-current liabilities | 7,909 | 7,798 | 7,474 |
| Other provisions 161 | 307 | 281 | 281 |
| Financial debt | 1,091 | 723 | 630 |
| Trade payables 18 | 1,337 | 1,431 | 1,439 |
| Income tax payables | 134 | 114 | 114 |
| Dividends payable | 4 | 154 | 154 |
| Other liabilities | 901 | 850 | 850 |
| Liabilities associated with assets held for sale | 475 | 454 | 435 |
| Current liabilities | 4,249 | 4,006 | 3,902 |
| Total equity & liabilities | 23,180 | 22,436 | 22,000 |
Impact of implementation of IFRS 16 from January 1, 2019:
maces of "Agent of the Collience of Collient of Colline of the relatives assess and essellines reast on the claimer dead to the poperios and essent of the reast of the reser
| Consolidated statement of changes in equity | Revaluation reserve (fair value) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in € million) | Share capital |
Share premiums |
I reasury shares |
Perpetua hybrid bonds |
Retained earnings |
Currency translation differences |
Equity instruments measured at fair value, hrough other comprehensive income |
Cash flow hedges |
Defined benefit pension plans |
Total reserves |
Non- controlling interests |
Total equity |
| Balance on December 31, 2017 | 1,588 | 1,170 | (281) | 2,188 | 6,454 | (834) | 5 | 16 | (୧୧୧୮) | 8,051 | 113 | 9,752 |
| Adoption IFRS 9 | (5) | (5) | (2) | |||||||||
| Balance on January 1, 2018 | 1,588 | 1,170 | (281) | 2,188 | 6,449 | (834) | 5 | 16 | (666) | 8,046 | 113 | 9,747 |
| Profit for the period | 109 | 109 | 10 | 118 | ||||||||
| Items of other comprehensive income | (795) | 3) | 22 | 128 | (649) | (1) | (150) | |||||
| Comprehensive income | - | 109 | (177) | (1) | 8 | 21 | (40) | ਰੇ | (32) | |||
| Cost of stock options | 3 | 3 | 3 | |||||||||
| Sale (acquisition) of treasury shares | 2 | 2 | 2 | |||||||||
| Balance on March 31, 2018 | 1,588 | 1,170 | (279) | 2,188 | 6,560 | (1,011) | 5 | 24 | (645) | 8,011 | 121 | 9,720 |
| Balance on December 31, 2018 | 1,588 | 1,170 | (299) | 2,486 | 6,834 | (618) | 9 | (26) | (636) | 8,920 | 117 | 10,624 |
| Adoption IFRS 16 | 8 | 8 | 8 | |||||||||
| Balance on January 1, 2019 | 1,588 | 1,170 | (299) | 2,486 | 6,842 | (618) | 9 | (26) | (636) | 8,928 | 117 | 10,632 |
| Profit for the period | 228 | 228 | 9 | 237 | ||||||||
| Items of other comprehensive income | 194 | 2 | (53) | 144 | ਤੇ | 147 | ||||||
| Comprehensive income | - | 228 | 194 | 2 | (23) | 372 | 12 | 384 | ||||
| Cost of stock options | 5 | 5 | 5 | |||||||||
| Coupons of perpetual hybrid bonds | (3) | (3) | (3) | |||||||||
| Sale (acquisition) of treasury shares | ട് | б | б | |||||||||
| Other | (2) | 1 | (1) | (1) | ||||||||
| Balance on March 31, 2019 | 1,588 | 1,170 | (293) | 2,486 | 7,070 | (423) | 10 | (24) | (689) | 9,306 | 128 | 11,023 |
[1] The decrease in 2018 and increase in 2019 in equity translation differences is mainly related to changes in the U.S. dollar to euro exchange rate.
Solvay is a public limited liability company governed by Belgian law and quoted on Euronext Paris. These condensed consolidated financial statements were authorized for issue by the Board of Directors on May 6, 2019.
On January 18, 2019, the European Commission clears of Solvays Polyamides activities to BASF, a key milestone in the completion of Solvays transformation interials and specialty chemicals company. The closing of the transaction is expected in the second part of 2019 after all remaining closing conditions will have been fulfilled. These conditions include the divestment of a remedy package to a third-party buyer to address the European Commission's competition concerns. BASF has offered remedies involving part of the assets originally in the acquisition. These entail among others the manufacturing assets of Solvays polyamide intermediates, technical fibers, and engineering plastics business as well as its innovation capabilities in Europe.
Solvay prepares its condensed consolidated interim financial statements on a quarterly basis, in accordance with IAS 34 "Interim Financial Reporting". They do not include all the information of the annual consolidated financial statements and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2018.
The condensed consolidated interim for the three morths ended March 31, 2019, were prepared using the same accounting policies as those adopted for the consolidated financial statements for the year ended December 31, 2018, except for the adoption of new standards and amendments effective as of January 1, 2019, that are discussed hereafter. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
As of January 1, 2019, the Group applied, for the first time, IFRS 16 "Leases", and the amendments to IAS 12 "Income Taxes" as part of the annual improvements to IFRS standards 2015-2017 cycle. As required by IAS 34 for condensed consolidated interim financial statements, the nature and effect of these changes are disclosed below.
Several other amendments and Interpretations apply for the first time in 2019, but do not have a more than insientificant impact on the condensed consolidated interim financial statements of the Group.
As from January1, 2019, the Group no longer applies IAS 17 "Leases", IFRC 4 "Determining whether an Arrangement contains a Lease", SIC-15 "Operating Leases - Incentives" and SIC-27 "Evaluating the Substance of Transactions Involving a Legal Form of a Lease". IFRS 16 is applicable for annual periods beginning on or after January1, 2019. IFRS 16 sets out the recognition, measurement, presentation, and disclosure of leases and requires lesses to account for all leases under a single on-balance sheet model, similar to the accounting for finance leases under IAS 17. At the commencement date of a lease liability (i.e. a liability (i.e. a liability to make lease payments), and a right-of-use asset (i.e. an asset representing the right to use the underlying asset over the lease term).
The Group's leased assets relate mainly to buildings, transportation equipment, and industrial equipment.
The right-of-use assets are presented in the consolidated statement of financial position, and the lease liabilities are presented as part of financial debt.
The following recorciliation to the opening balance for the lease liability as at January 1, 2019 is based upon the operating lease obligations as at December 31, 2018:
| (in € million) | January 1, 2019 |
|---|---|
| Total of future minimum lease payments under non-cancellable operating leases (undiscounted) at December 31, 2018 | 491 |
| Minimum lease payments of finance leases (undiscounted) at December 31,2018 | 90 |
| Other | 74 |
| Lease liabilities (undiscounted) at January 1, 2019 | 606 |
| Discounting | (137) |
| Present value of minimum lease payments of finance leases at December 31,2018 | (36) |
| Additional lease liabilities as a result of the initial application of IFRS 16 as at January 1, 2019 | 433 |
"Other" mainlyincludes onerous lease contracts, previously recognized in "Other provisions" for €16 million, and accrued lease payments, previously included in "Trade payables" for €8 million.
As a result of the adoption of IFRS 16, for the first quarter of 2019, depreciation and finance expense increased by €25 million and €4 million, respectively, and operating expersed by €(26) million. In addition, the operating cash flows increased by £26 million, against a decrease of financing cash flows.
As from January 1, 2019, the Group applies the amendments to IAS 12, that apply to the income tax consequences of dividends recognized on or after the beginning of the earliest comparative period, i.e. January 1, 2018.
In 2018, the income tax consequences of the coupons on perpetual hybrid bonds classified in equity. As a result of the adoption of the amendment, those income tax consequences will be recognized in profit or loss.
| (in € million) | 01 2018 | 02 2018 | 03 2018 | 04 2018 | FY 2018 | |
|---|---|---|---|---|---|---|
| Profit for the period, IFRS as published | ದ | 118 | 235 | 288 | 257 | 897 |
| Tax on hybrids in equity | b | 15 | 5 | 19 | ||
| Profit for the period, IFRS restated | c = a+b | 118 | 249 | 288 | 261 | 917 |
| Profit for the period attributable to non-controlling interests, IFRS restated |
d | 10 | 9 | 11 | 9 | ਤੇਰੇ |
| Profit for the period attributable to Solvay shareholders, IFRS restated |
e = c-d | 109 | 240 | 277 | 252 | 877 |
| Weighted average of number of outstanding shares, basic |
f | 103,354,210 | 103.275.653 | 103.277.950 | 103,198,714 | 103.276.632 |
| Basic earnings per share (in €), IFRS restated | g = e/f | 1.05 | 2.32 | 2.68 | 2.44 | 8.49 |
In the cash flow statement, increase in "Profit for the period" is offset by lower "Income tax expenses";
In the statement of changes in equity, increase in "Profit for the period" is offset by lower "Other" changes in "Retained Earnings".
At inception of a contract, which generally coincides with the date the contract is signed, the Group assesses whether a contract is, or contains, a lease. A contract is, or contact conveys the right to control the use of an identified asset for a period of time in exchange for consideration.
An asset is typically identified by being explicity specified in a contract. However, an asset can also be identified by being implicity specified at the time that the asset is made available for use by the customer. If the substantive substitution right, then the asset is not identified.
To assess whether a contract conveys the use of an identified asset, the Group assesses whether, throughout the period of use, it has:
The Group determines the lease term as the non-cancellable period of a lease, together with both:
In its assessment, the Group considers the impact of the following factors (non-exhaustive):
The Group recognizes a right-of-use asset and a lease commencement date, which is the date that the lessor makes the asset available for use by the Group.
The right-of-use asset is initially measured at cost, which comprises:
After the commencement date, the right-use asset is measured at cost less any accumulated impairment losses. Right-of-use assets are depreciation method, from the commencement date to (a) the end of the useful life of the underlying asset, in case transfers ownership of the underlying asset to the Group by the end of the lease term, or the lease contains a purchase option that the Group is reasonably certain to execcise, or (b) the end of the useful life and the end of the lease term, in all other cases.
The lease liability is initially measured at the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be respective Group entity's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise the following:
Service components (e.g. utilities, maintenance, ..) are excluded from the measurement of the lease liability.
After the commencement date, the lease liability is measured by:
Tax impacts relating to the coupons of perid bonds classified as equity are recognized in profit or loss, to the extent that they are considered to stem from past transactions or events that generated distributable profits.
Solvay is organized in the following operating segments:
| (in € million) | Q1 2019 | 01 2018 |
|---|---|---|
| Net sales | 2,571 | 2,492 |
| Advanced Materials | 1,124 | 1,087 |
| Advanced Formulations | 728 | 730 |
| Performance Chemicals | 718 | 671 |
| Corporate & Business Services | 2 | 4 |
| Underlying EBITDA | 571 | ਦੇਤੇਤ |
| Advanced Materials | 290 | 288 |
| Advanced Formulations | 126 | 118 |
| Performance Chemicals | 206 | 177 |
| Corporate & Business Services | (51) | (51) |
| Underlying depreciation, amortization & impairments | (195) | (163) |
| Underlying EBIT | 376 | 370 |
| Non-cash accounting impact from amortization & depreciation of purchase price allocation (PPA) from acquisitions |
(54) | (57) |
| Net financial charges and remeasurements of equity book value of the RusVinyl joint venture | 7 | (6) |
| Result from portfolio management & reassessments | (35) | (145) |
| Result from legacy remediation & major litigations | (16) | (18) |
| FRIT | 278 | 144 |
| Net financial charges | (54) | (51) |
| Profit for the period before taxes | 225 | ਰਤੋ |
| Income taxes | (53) | (12) |
| Profit for the period from continuing operations | 172 | 81 |
| Profit (loss) for the period from discontinued operations | 65 | 37 |
| Profit for the period | 237 | 118 |
| attributable to non-controlling interests | 9 | 10 |
| attributable to Solvay shareholders | 228 | 109 |
The Q1 2018 figures have been prepared using IAS 17. The pro forma Q1 2018 figures, prepared using IFRS 16 have been published outside the IFRS financial statements, and were included in the fourth quarter 2018 Financial Report.
[1] The nor-ash PPA impacts can be found in the reconcliation able on page 12. For 0.209 these consist of intengible assets, which are adjusted in "Administrative costs" for €8 million, in "Research & development costs" for €1 million, and in "Other operating gains & losses" for €46 million.
Compared to December 31, 2018, there are no changes in valuation techniques.
For all financial instruments not measured at fair value in Solvay's consolidated statement of financial of those financial instruments as of March 31, 2019, is not significantly different from the ones published in Note F35 of the consolidated financial statements for the year ended December 31, 2018.
For financial instruments measured at fair value in Solvay's consolidated statement of financial position, the fair value of those instruments as of March 31, 2019, is not significantly different from the ones as published in the Note F35 of the consolidated financial statements for the year ended December 31, 2018.
On April 3, 2019, Solvay announced that its subsidiary Solvay Finance SA will exercise its first call option on its €700 million hybrid bond (ISIN XS0992293570 / Common Code 099229357). This perpetual deeply subordinated bond, bearing an annual interest rate of 4.199%, is treated as equity under IFRS rules. Its repayment is due on May 12, 2019 at the first 5.5 years. This operation follows the successful issuance of €300 million perpetual hybrid bond with a coupon of 4.25% on December 4, 2018. As a result, the overall quantum of hybrid bonds in Solvay's balance sheet, which rose from €2.5 billion at the end of 2018, will decrease to €1.8 billion by mid-2019.
llham Kadri, Chief Executive Officer, and Karim Hajjar, of the Solvay Group, declare that to the best of their knowledge:

First half 2019 results
February 26, 2020 Full year 2019 results
" Press release

| Investor relations |
Geoffroy Raskin +37 7 764 1540 [email protected] |
Jodi Allen +1 609 860 46 iodi.allen@so |
|---|---|---|
Media Caroline Jacobs relations +32 2 264 1530
୧୦୫ lvay.com Bisser Alexandrov +32 2 264 3687
Victoria Binoche +33 1 44 94 86 72 [email protected]

This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this and uncertainties relating to a number of factors, interest ate and foreign currency exchange rate fluctuations, changing market condition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&l projects and other unusual items. Consequently, actual results or future events maydiffer materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results com those anticipated. The Company undertakes no oblicly update or revise any forward-looking statements

Solvay is an advanced materials and specialty chemitted to developing chemistry that addresses key societal challenges. Solvay innovates and partners worldwide in many diverse end markets. Its products are used in planes, cars, batteries, smart and medical devices, as well as in mineral and oil & gas extraction, enhancing efficiency and sustainability. Its lightweighting materials promote cleaner mobility, its formulations optimize the use of resources and its performance chemicals improve air and water quality.
Solvay is headquartered in Brussels with around 24,500 employees in 62 countries. Net sales were €10.3 billion in 2018, with 90% from activities where Solvay ranks among the world's top 3 leaders, resulting in an EBITDA margin of 22%. Solvay SA (SQLB.BE) is listed on Euronext Brussels and Paris Bloomberg: SOLB.BB - Reuters: SOLB.BB) and in the United States its shares (SOLV) are traded through a level-1 ADR program. (Figures take into account the announced divestment of Polyanides)




Contact us [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.